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Abstract
Significant scientific progress has been achieved in the past decade in thyroidology driven by scholarly enquiry, unmet patient
needs, and investment by the pharmaceutical and diagnostics industry. In this review, nine publications have been selected for
their impact in pushing the frontiers of knowledge and understanding. They include new perspectives in the diagnosis, patho-
physiology, epidemiology and management of thyroid cancer, understanding of thyroid hormone physiology, and new treatments
for Graves’ orbitopathy.
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Introduction
Reflecting on advances made in thyroidology over the past
decade is interesting and relatively easy. However, passing
verdict on the most significant publications is a major chal-
lenge fraught with the risk of doing injustice to important
work while overstating trivia. One approach is to base judge-
ment on citations [1]. This is a well-established scientific
method and lets one off the hook by transferring responsibility
to an anonymous process with its own peculiarities and intri-
cacies. A serious drawback is the time bias associated with
citations, with older publications being more likely to be cited
than recent ones. Another approach is to pick out highly
respected journals with themost rigorous peer reviewers; what
can possibly go wrong? Well, a number of such papers imme-
diately come to mind from the not-so-distant past which sim-
ply did not stand up to the test of independent reproducibility
and are now only remembered for the wrong reasons. That left
the author with one option: to use his own subjective judge-
ment based on impact on clinical practice and understanding
of thyroid pathophysiology. Nine papers were selected that
had been published in the past decade and which broadly
cover the main topics of thyroidology (Table 1). [2–10]
Thyroid cancer and nodules
The epidemic
In the past decade, we have witnessed a constant rise, and
currently an exponential increase, in the incidence of thyroid
cancer, which is affecting several countries, yet mortality has
remained stable [11]. Increased detection has been proposed
as the principal causative factor [12], although the latter ex-
planation has been disputed [13, 14]. Themost robust data that
have explored this controversial issue come from South
Korea, the country where the epidemic shows the most spec-
tacular rise in incidence. Ahn and colleagues [9] performed an
observational retrospective study, using national data, on the
incidence of thyroid cancer, screening rates, and mortality in
their country. It was observed that opportunistic screening for
thyroid cancer by ultrasound crept into almost all routine prac-
tice in South Korea following the introduction of screening for
breast and ovarian cancer, though screening rates for thyroid
cancer varied in different regions. The authors were able to
show a positive linear relationship between screening rates
and diagnosis of thyroid cancer, while mortality remained
low and unchanged. This work provides convincing evidence
that screening of the general population for thyroid cancer
leads to detection of small papillary thyroid cancers, which
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are largely of no clinical relevance. It lends support to the view
that clinicians should exercise restraint before performing thy-
roid ultrasonography, which should only be undertaken when
there is a clinical indication [15]. One question that remains
unanswered is whether screening for thyroid cancer may be
appropriate in selected subgroups. A significant proportion of
patients who die from thyroid cancer are older people (often
men) who present late with aggressive dedifferentiated can-
cers. Most of these are presumed to have a lengthy prodrome
of occult differentiated thyroid cancer, which potentially pre-
sents a window of opportunity for detection and effective
treatment.
Genetic landscape
The Cancer Genome Atlas project was established in 2006 in
the USA and has been generously funded with the aim of
performing large-scale cancer genome sequencing. Lawrence
et al. [5] studied 3087 tumour/normal tissue pairs across 27
tumour types, including papillary thyroid cancer. Whole-
exome and whole-genome sequencing was used to study the
samples. One of the novel aspects of the study was the devel-
opment of an analytical methodology for dealing with false-
positive results. The principal finding of interest from the point
of view of thyroid cancer was that the rate of non-silent muta-
tions was very low (0.41/Mb). It was thus determined that
papillary thyroid cancers are genetically among the simplest
of human cancers. The significance of this finding is that un-
derstanding the relationship between driver mutations, genes,
histology and biological behaviour is within reach with relative
ease. Such knowledge has the potential to improve diagnostic
methods and personalise treatment for thyroid cancer.
Papillary thyroid microcarcinomas
Papillary thyroid microcarcinomas are common [16, 17], asso-
ciated with a good prognosis, [18, 19] and often treated with
thyroid lobectomy. Investigators from the Kuma Hospital in
Japan have approached the management of such patients in a
more conservative manner (70). This study included patients
with proven papillary microcarcinomas based on cytology who
had no local or distant metastases, no aggressive cytology and
no evidence of local invasion. Patients were offered immediate
lobectomy or active surveillance (thyroid ultrasound at
6 months and then annually). More than 1000 patients have
been followed up for about 10 years. The majority (nearly
90%) have remained stable, about 8% have shown increase in
the size of the tumour and 3.8% developed cervical lymph node
metastases. Patients who progressed were treated surgically. To
date, no patient has died or developed distant metastases.
Interestingly, older patients were less likely to progress than
younger ones. It was estimated that active surveillance cost four
times less than immediate lobectomy, while the study also doc-
uments the natural history of papillary microcarcinomas and
confirms an indolent course for the majority. This knowledge
is already impacting clinical practice and is reflected in recent
guidelines [15]. There would be undoubted benefits in being
able from the outset to predict which patients will progress, and
further research in this area is under way.
Thyroid ultrasound in risk stratification of thyroid
nodules
The golden standard in the workup of thyroid nodules is fine
needle aspiration cytology (FNAC); however, a significant
proportion (about 25%, [20]) of FNACs are indeterminate
and diagnostic surgery is often required. Ultrasound of the
thyroid can provide information about the likelihood of ma-
lignancy of thyroid nodules. The TIRADS scoring systemwas
developed to provide an objective risk stratification tool [21,
22]. On the other hand, while reliable in a research setting, it
was not easily transferrable to routine clinical practice.
Investigators from Paris modified TIRADS to a simpler ver-
sion, which appeared to perform well in a retrospective series
[23]. It was followed by a large prospective, single-centre
study of more than 4000 nodules with corresponding cytology
Table 1 Selected publications in thyroidology in the past decade (in
chronological order)
1. Atzmon G, Barzilai N, Surks MI, Gabriely I. Genetic predisposition to
elevated serum thyrotropin is associated with exceptional longevity. J
Clin Endocrinol Metab. 2009;94:4768–-4775 (2)
2. Marcocci C, Kahaly GJ, Krassas GE, Bartalena L, Prummel, M, Stahl
M, et al., 2011 Selenium and the course ofmild Graves'’ orbitopathy. N
Engl J Med 364: 1920–-1931 (3)
3. ChudovaD,Wilde JI,Wang ET,WangH, Rabbee N, Egidio CM, et al.,
2010 Molecular classification of thyroid nodules using
high-dimensionality genomic data. J Clin Endocrinol Metab
95:5296–-5304 (4).
4. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K ,
Sivachenko A, et al. 2013 Mutational heterogeneity in cancer and the
search for new cancer associated genes. Nature 499: 214–-218 (5).
5. Russ G, Royer B1, Bigorgne C, Rouxel A, Bienvenu-Perrard M,
Leenhardt L, 2013 Prospective evaluation of thyroid imaging reporting
and data system on 4550 nodules with and without elastography. Eur J
Endocrinol 168: 649–-655 (6).
6. Ito Y, Miyauchi A, Kihara M, Higashiyama T, Kobayashi K, Miyaat A
2014 Patients age is significantly related to the progression of papillary
microcarcinoma of the thyroid under observation Thyroid 24: 27–-34
(7).
7. Werneck de Castro JP, Fonseca TL, Ueta CB, McAninch EA, Abdalla
S, Wittmann G, et al., 2015 Differences in hypothalamic type 2
deiodinase ubiquitination explain localizedlocalised sensitivity to
thyroxine. J Clin Invest 125: 769–-781 (8).
8. Ahn HS, Kim HJ, Kim KH, Lee YS, Han SJ, Kim Y, et al. Thyroid
cancer screening in South Korea increases detection of papillary
cancers with no impact on other subtypes or thyroid cancer mortality.
Thyroid. 2016;26:1535–-1540 (9).
9. Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang, RA,
et al., 2017 Teprotumumab for thyroid-associated ophthalmopathy. N
Engl J Med 376: 1748–-1761 (10).
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or histology [6]. Benign nodules were assigned a score of 2
and malignant a score of 5. The data showed a very high
positive predictive value for a score of 5 and a very low risk
of cancer in nodules with a score of 2. Furthermore, interob-
server reproducibility was high and it was estimated that use
of this diagnostic tool reduced the need for FNAC by a third.
The importance of this study is that it provided a simple scor-
ing system that performs well, can be learned relatively easily
and can be applied effectively in clinical practice. Including
this step in the diagnostic workup of thyroid nodules removes
the need to proceed to FNAC in a significant proportion of
patients. Its weakness is that those patients with a score of 3 or
4 continue to present a management challenge.
Molecular markers in FNAC material
In another study, investigators from 10 academic centres in the
USA utilised molecular markers on FNAC material for the
diagnosis of thyroid cancer [4]. Messenger RNAwas extract-
ed and many thousands of transcripts were generated and
analysed. Surgical specimens were used initially, followed
by FNAC material, and finally a small prospective (n = 48)
set of FNAC samples from patients with nodules, including
some with indeterminate cytology (n = 24). The authors con-
cluded that the test had a high negative predictive value and
specificity. The markers used in this study remain undisclosed
and the test is now commercially available. Since then, several
other kits have come on the market. These tests are promising
but require further validation for routine clinical use and at
present appear to be overpriced.
Hypothyroidism
Thyroid hormone replacement
Doctors in several developed countries are seeing ever greater
numbers of patients with a diagnosis of hypothyroidism who
complain that their hypothyroid symptoms are not completely
resolved with levothyroxine (T4) therapy. This seems to affect
about 10% of hypothyroid patients [24, 25], including patients
with apparently well-controlled hypothyroidism (TSH within
the normal reference range, [26]), leading to the hypothesis
that T4monotherapy may not be capable of completely restor-
ing thyroid status [27]. Combination therapy with T4 and
liothyronine (T3) is equally ineffective [28], perhaps because
of the pharmacokinetics of T3 resulting in peaks and troughs
in serum levels. Understanding of this clinical conundrum at
the molecular level remains unclear. Antonio Bianco’s group
has addressed this dilemma through a series of elegant exper-
iments using the thyroidectomised rat as a model [8]. Animals
were rendered hypothyroid and replaced with T4 alone, T4
and T3 boluses or a continuous supply of T4 and T3. Serum
TSH was normalised in all three groups; however, normal
serum FT3, tissue levels of T3 and expression of T3-
regulated genes were achieved only in the group of animals
treated with a continuous supply of T4 and T3. They also
showed that the mechanism behind these differences involves
ubiquination of D2, which differs in the hypothalamus (the
regulator of TSH secretion) as compared to the rest of the
brain. The significance of these findings is that they provide
a plausible explanation for why T4 monotherapy may not
relieve all hypothyroid symptoms in patients. Clearly, further
studies in humans are required to explore this further.
The thyroid axis in the very elderly
It has been known for a long time that thyroid function declines
with old age, independently of antithyroid autoantibodies and
comorbidities [29, 30]. It has also been noted that mortality
among people older than 85 years is lower in those with a
TSH> 4.8 mU/L [31]. Atzmon G et al. [2] performed a study
of 232 Ashkenazi Jewish people with a median age of 97 years.
They were compared with a group of offspring (median age
67 years), the offspring’s spouses (median age 66 years) and
an unrelated Ashkenazi Jewish group of people with a median
age of 75 years. Themedian serumTSH of offspring of the very
old group was shifted to the right of the control group, while
that of the very elderly group was even further to the right.
Further analysis showed a moderate heritability effect and as-
sociations between serum TSH in the very old and certain TSH
receptor SNPs. This study confirms that subclinical hypothy-
roidism in very old age is not disadvantageous and may be
partially genetically determined. Clinicians are advised to tol-
erate mild TSH elevation in people over the age of 80 years.
Graves’ orbitopathy
The IGF-1 receptor and Graves’ orbitopathy
It has been known for some time that IGF-1 receptors are
expressed in orbital tissues [32] and that TSH and IGF-I have
a synergistic effect on growth and proliferation of thyrocytes
[33]. In one study, Graves’ IgG was able to stimulate hyaluran
production by orbital fibroblasts, and this effect seemed to be
mediated via the IGF-1 receptor [34]. Teprotumumab is an
IGF-1 receptor blocker developed as an anticancer drug but
which failed phase I trials for efficacy. Based on the above
evidence that the IGF-1 receptor may be involved in Graves’
orbitopathy, a study was performed [10]. The study was a
prospective, multicentre, randomised, placebo-controlled trial
which recruited patients with moderate to severe disease with
a clinical activity score > 4 and disease duration < 9 months.
Eight infusions of teprotumumabwere administered at 3-week
intervals. Eighty-seven patients were studied. Response was
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assessed at 24 months. The overall response rate was far su-
perior with teprotumumab compared to placebo. The most
remarkable observation was that teprotumumab was associat-
ed with an average 3 mm reduction in proptosis. This level of
efficacy on proptosis has never been seen with medical treat-
ments and is of great interest, as it may eliminate the need for
surgical decompression in suitable patients.
Selenium and Graves’ orbitopathy
It has been suggested that free radical generation may play a role
in the pathogenesis of Graves’ orbitopathy [35, 36]. Since
selenoproteins act as antioxidants [37], a role for selenium as
an immune modulator [38] is possible. This led the European
Group On Graves’ Orbitopathy (EUGOGO) to perform a study
comparing selenium supplements with placebo [3]. The study
was prospective, multicentre and randomised and recruited pa-
tients with mild, active Graves’ orbitopathy (clinical activity
score > 3), with a disease duration < 7months. Fifty-four patients
were randomised to selenium selenite 100 mcg bd and 50 to
placebo. Patients were treated for 6 months. The overall re-
sponseswere significantly better in the seleniumgroup compared
to placebo, including a marked improvement in quality of life.
Furthermore, fewer patients treated with selenium progressed to
more severe disease. This study is remarkable for several reasons:
it was completed with minimum funding amounting to no more
than a few thousand Euros to cover the cost of the drug and
placebo; it shows efficacy of a treatment which is tolerated ex-
tremely well; the treatment costs 15–20 Euros per patient; be-
cause mild Graves’ orbitopathy is so much more common than
other variants of Graves’ orbitopathy, the impact of this treatment
at a population level is probably greater than that of any other
intervention for Graves’ orbitopathy. The precise mechanism of
action of selenium supplements continues to be unclear.Whether
seleniummay have a role in prevention of Graves’ orbitopathy is
unknown and is currently under investigation. [39]
The future
Speculating about future advances in thyroidology is to some
extent safe and can be based on extrapolations from current
trends. With regard to therapeutics, publications are anticipat-
ed of numerous on-going studies of tyrosine kinase inhibitors
in advanced thyroid cancer. Immunotherapies for autoimmune
thyroid disease are also emerging [40], and we may see a
return of interest in thyroid hormone agonists [41]. A slow
release T3 preparation is expected to become available and
clinical studies in hypothyroidism are sure to follow [42].
TSH receptor inhibitors, both monoclonal antibodies and
small molecules, will also feature [43]. In basic research, we
can expect to learn more about the application of regenerative
medicine in thyroidology [44] and we will hear a lot more
about the role of thyroid hormones in dementia [45]. The
general themes that are likely to prevail include personalised
medicine (especially as applied to the management of thyroid
cancer), data mining and artificial intelligence, all of which are
already beginning to be introduced into thyroidology [46, 47].
The author has threemajor aspirations for the next 10 years.
One is that clinicians will work towards reversing the tide of
unnecessary investigations and treatments for thyroid nodules
and incidental thyroid cancers, which has an enormous nega-
tive impact on patient care and wastes large amounts of re-
sources. The second is that the high expectations about tyro-
sine kinase inhibitors in advanced thyroid cancer will eventu-
ally translate to clinically meaningful outcomes and that these
drugs may become affordable. And finally and most impor-
tantly, the global elimination of iodine deficiency.
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